Bafna (BAFNAPH) | Stock Overview & Key Data
Bafna Performance Comparison
Stock Range
Today's Range
Low: ₹94.54
High: ₹104.49
on August 22, 2025
52 Week Range
Low: ₹69.00
High: ₹114.97
on February 19, 2025
on August 19, 2025
All-Time High: ₹233.55 on December 14, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR2.4B
EPS
3.50
P/E Ratio (TTM)
28.29
Forward P/E
N/A
P/B Ratio
2.78
PEG Ratio
-0.05
Div. Yield
N/A
ROE
4.90%
Beta
0.189
Debt to Equity
33.25
Financial Highlights
Profitability
Gross Margin
35.25%
Operating Margin
10.68%
Profit Margin
5.62%
Returns and Earnings
Return on Assets (TTM)
2.71%
Return on Equity (TTM)
4.90%
EBITDA
INR178.7M
Net Income (TTM)
INR82.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR62.22
Quarterly Revenue Growth (YoY)
4.00%
Quarterly Earnings Growth (YoY)
4.02%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bafna BAFNAPH | 2.35B Small-cap | -16.65% | 7.60% | 29.41% | 29.93% | 15.71% | 18.38% | -16.69% | 307.49% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | -2.16% | -4.47% | 0.14% | -13.13% | -7.54% | 86.54% | 195.42% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -0.21% | -6.98% | -5.91% | 7.87% | 1.29% | 26.68% | 71.47% | 87.96% |
| Sun Pharma Advanced SPARC | 47.77B Small-cap | 1.72% | -7.23% | -10.11% | 14.74% | -27.21% | -34.43% | -37.13% | -23.18% |
| Aarti Drugs AARTIDRUGS | 42.99B Small-cap | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% | -14.34% | 10.27% | -34.08% |
| Sequent Scientific SEQUENT | 44.30B Small-cap | 0.12% | -6.92% | -2.35% | 12.64% | -4.77% | 5.41% | 52.52% | 30.60% |
Ownership & Short Interest
Insider Ownership
87.79%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
35K
Average 90-Day Volume
14K
Bafna Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Bafna would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BAFNAPH's 52-week high and low?
- In the last 52 weeks, Bafna reached a high of ₹114.97 (on August 19, 2025) and a low of ₹69.00 (on February 19, 2025).
- What is the market cap and P/E ratio for BAFNAPH?
- Curious about Bafna's size and valuation? Its market capitalization stands at 2.35B. When it comes to valuation, the P/E ratio (trailing twelve months) is 28.29, and the forward P/E (looking ahead) is N/A.
- Does BAFNAPH pay dividends? If so, what's the yield?
- As for dividends, Bafna isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bafna's main competitors or similar companies to consider before investing?
When looking at Bafna, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -7.54% 86.54% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 26.68% 71.47% Sun Pharma Advanced
SPARC47.77B Healthcare Drug Manufacturers - Specialty & Generic -34.43% -37.13% Aarti Drugs
AARTIDRUGS42.99B Healthcare Drug Manufacturers - Specialty & Generic -14.34% 10.27% Sequent Scientific
SEQUENT44.30B Healthcare Drug Manufacturers - Specialty & Generic 5.41% 52.52% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bafna Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Bafna's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.90%, the Debt to Equity ratio from the most recent quarter is 33.25, and its Gross Profit Margin stands at 35.25%.
- What is the recent revenue and earnings growth for BAFNAPH?
- Looking at Bafna's growth, its revenue over the trailing twelve months (TTM) was INR1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.00%, and quarterly earnings saw a YoY growth of 4.02%.
- How much of BAFNAPH stock is held by insiders and institutions?
- Wondering who owns Bafna stock? Company insiders (like executives and directors) hold about 87.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.